{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Powerful NeOnc Brain Cancer Pipeline Advances - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Vdx7fddnY9\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/powerful-neonc-brain-cancer-pipeline-advances\/\">Powerful NeOnc Brain Cancer Pipeline Advances<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/powerful-neonc-brain-cancer-pipeline-advances\/embed\/#?secret=Vdx7fddnY9\" width=\"600\" height=\"338\" title=\"&#8220;Powerful NeOnc Brain Cancer Pipeline Advances&#8221; &#8212; Market Newsdesk\" data-secret=\"Vdx7fddnY9\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"November 17 FDA Meeting Set to Discuss Dosing and Trial Size for Second Drug in Pipeline DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; (247marketnews.com) &#8212; NeOnc Technologies Holdings (NASDAQ: NTHI) is putting another major date on the biotech calendar: November 17, 2026, when the company is scheduled to meet with the U.S. Food and Drug Administration for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212. The meeting could become an important inflection point for a company that has rapidly assembled a string of clinical, regulatory and Wall Street catalysts. NeOnc says it plans to seek FDA feedback on NEO212\u2019s proposed patient population, trial design, endpoints, dose selection and the evidence that could ultimately support a &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTAyNSM3ODY2NTkwIzUwMDE2MjE5NA=="}